2-11-16 $CTIX ~ Cellceutix Corp. Due Diligence Report

New Post Public Reply Private Reply Replies (1) Message Board

Feb 11, 2016 at 11:18 AM

2-11-16 $CTIX ~ Cellceutix Corp. Due Diligence Report

$CTIX recent news

PR's from Cellceutix:

http://www.cellceutix.com/category/press-rele...r967e.dpbs

PR's from Yahoo/Marketwired:

Wed, 10 Feb 2016 ~ Cellceutix Meets With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian Cancer

read full: http://www.marketwired.com/press-release/cell...095727.htm

Tue, 9 Feb 2016 ~ Cellceutix to Submit Special Protocol Assessment Request to FDA for Phase 3 Clinical Study of Antibiotic Brilacidin for ABSSSI

read full: http://cellceutix.com/cellceutix-to-submit-sp...NHL8K.dpuf

Mon, 25 Jan 2016 ~ Cellceutix Phase 2 Trial of New Oral Treatment for Psoriasis Nearing Completion

read full: http://www.finance.yahoo.com/news/cellceutix-...00315.html

Fri, 22 Jan 2016 ~ Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer

read full: http://www.finance.yahoo.com/news/cellceutix-...42403.html

Thu, 21 Jan 2016 ~ Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Pancreatic Cancer

read full: http://www.finance.yahoo.com/news/cellceutix-...58464.html

Tues, 19 Jan 2016 ~ Cellceutix Submits Briefing Book for Phase 2 Trial of p53 Targeting Drug for Ovarian Cancer

read full: http://www.marketwired.com/press-release/cell...089125.htm

Thurs, 14 Jan 2016 ~ Brilacidin Lyophilized as Cellceutix Prepares to Bring First New Class of Antibiotic to Phase 3 Trials in More Than 20 Years

read full: http://www.marketwired.com/press-release/bril...088217.htm

$CTIX filings - Perhaps the most important section

http://www.sec.gov/cgi-bin/browse-edgar?compa...getcompany

$CTIX charts

basic chart ## source: stockscores.com

$CTIX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CTIX/company-info
Ticker: $CTIX
OTC Market Place: OTC Pink Current
CIK code: 0001355250
Company name: Cellceutix Corp.
Company website: http://www.cellceutix.com
Incorporated In: NV, USA

Additional $CTIX company information:

## source: Opinion summary from various sources.

Business Description: Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. This trial just completed its final cohort. Plans for a Ph 2/3 Ovarian Cancer Study are underway. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is currently conducting a Phase 2 clinical trial under Fast Track Designation with its novel compound Brilacidin-OM for the prevention and treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound, has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol is presently in Phase 2 trial. Enrollment is complete. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s key antibiotic, Brilacidin, recently completed a successful Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Plans for a phase 3 trial are underway w/ FDA's approval. Brilacidin has the potential to be a single-dose therapy or a dosing regimen that is shorter than currently marketed antibiotics for multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. Please click on the below link to find for more information on completed and active Human Clinical Trials.

https://www.clinicaltrials.gov/ct2/results?te...rch=Search

$CTIX Share Structure

## source: otcmarkets.com

Market Value: $132,602,100 a/o Feb 09, 2016
Shares Outstanding: 118,500,536 a/o Oct 31, 2015
Float: Not Available
Authorized Shares: 300,000,000 a/o May 12, 2008
Par Value: 0.0001

Various $CTIX DD links

Cellceutix Corp. website - http://www.cellceutix.com
Company Email - info@cellceutix.com
Management - http://cellceutix.com/team/
Product Pipeline - http://cellceutix.com/pipeline/
Recent News and Press Releases - http://finance.yahoo.com/q/h?s=CTIX+Headlines
SEC Filings - http://www.sec.gov/cgi-bin/browse-edgar?compa...getcompany
Financials - http://www.otcmarkets.com/stock/CTIX/financials
Transfer Agent - http://www.westcoaststocktransfer.com/
Short Interest - http://www.otcmarkets.com/stock/CTIX/short-sales
Key Statistics - http://www.finance.yahoo.com/q/ks?s=CTIX+Key+Statistics
Insider Roster - http://www.finance.yahoo.com/q/ir?s=CTIX+Insider+Roster
Insider transactions - http://www.secform4.com/insider-trading/CTIX.htm
Income Statement - http://finance.yahoo.com/q/is?s=CTIX
Balance Sheet - http://www.finance.yahoo.com/q/bs?s=CTIX
Cash Flow - http://www.finance.yahoo.com/q/cf?s=CTIX+Cash...amp;annual

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?...pact=false
WIPO
http://www.wipo.int/patentscope/search/en/det...ing=FP src="/images/icons/icon_sad.gif" class="post_smiley" /> Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sec...amp;d=PG01

http://patft.uspto.gov/netacgi/nph-Parser?Sec.../8,796,275

********************************************************

**The below section courtesy of Slcimmuno**

1) PIPELINE MILESTONES/CATALYSTS

Oncology

- Completion of K Phase 1 (Solid Tumor) -- article has been submitted to a peer review journal for publication

- Initiation of several other K Phase 2, 2/3 trials -- ovarian, pediatric retinoblastoma, pancreatic, AML... this last one w/ Bologna on hold pending financing; in future trials, K to be evaluated as a monotherapy and as a combo therapy; more frequent dosing likely (eg, 2-3x week); company pursuing outside grant support; addtl Orphan designations possible beyond the two already awarded for ovarian, pediatric retinoblastoma; more expedited pathway designations possible, e.g., Breakthrough Therapy

See:
http://www.fda.gov/downloads/AboutFDA/Centers...447162.pdf

Infectious Disease / Antibiotics

- Start of B-ABSSSI Phase 3 -- Brilacidin represents a new class of ABX, Host Defense Protein (HDP)-Mimics; given as a single dose (in Ph 2 compared favorably w/Daptomycin); two trials, approximately 1400 patients btw them; also a Pediatric Study Plan submitted to FDA for use in children; eventual Fast-Track designation, per QIDP

See:
https://en.wikipedia.org/wiki/Brilacidin

See:
http://www.researchgate.net/profile/Chandradh...8a1ca5.pdf

- Phase 2 B-OM (oral mucositis) -- FDA has granted Fast Track status; great unmet need here; recruitment ongoing, additional enrollment sites being pursued

- ABX platform progress -- advancing work on anti-fungals (Candida species, aspergillus); anti-biofilm (MTA signed for B-prophylactic testing with a Big Rx); gram-neg compounds targeting Pseudomonas, Klebsiella, E. Coli, Acinetobacter. Carbapenem-resistant Enterobacteriaceae (CRE); GI indiciations, givien B's immunomodulatory properties (Ulcerative Proctitis/Colitis, H Supportiva); topical applications for Otic Infections

Dermatology

- Phase 2 Prurisol update -- enrollment is complete (plaque psoriasis)

2) OPERATIONS

- Financing in place (shelf, Aspire)
- 1st Shareholder meeting (Dec 15)
- NASDAQ uplisting
- Class Action Defense (Legal/Sullivan)
- Partners: more a question of when not if as science continues to prove out -- could happen anytime. One case study, see CELG-Nurix deal (p53)

https://blogs.shu.edu/cancer/2015/09/30/ubiqu...d-celgene/

3) CURRENT TRIALS

http://www.clinicaltrials.gov/ct2/results?ter...rch=Search

1. P (Phase 1, Successful Completion): http://clinicaltrials.gov/ct2/show/NCT0210121...amp;rank=1

P (Phase 2, Active, Not Recruiting): http://www.clinicaltrials.gov/ct2/show/NCT024...amp;rank=2

2. B-OM (Phase 2, Active, Recruiting): http://www.clinicaltrials.gov/ct2/show/NCT023...amp;rank=3

3. K (Phase 1, Active, Not Recruiting): http://www.clinicaltrials.gov/ct2/show/NCT016...amp;rank=4

4. B-ABSSSI (Phase 2, Successful Completion): http://www.clinicaltrials.gov/ct2/show/NCT020...amp;rank=5

Abbreviations

K – Kevetrin
B – Brilacidin
P – Prurisol
OM – oral mucositis
ABSSSI – acute bacterial skin and skin structure infections
QIDP – qualified infectious disease product

Company Website:
http://www.cellceutix.com

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Deciding Between Root Canal or Tooth Extraction

The Battle Between Saving and Extracting Teeth No one really talks about teeth as if they hold the keys to happiness, but let’s face it, the difference between chewing a juicy steak and wincing with every bite can be the fate of a single tooth. Dr. Carey Norton from Dacula Family Dentistry breaks down when a root canal can be an oasis of hope and when extraction is the...

ZKONG, Hagebau Push ESLs in European Retail Revamp

ESLs: The Next Step in Retail Revamp Here’s the scoop: ZKONG and hagebau are making waves in the retail scene over in Germany. They’re bringing in Electronic Shelf Labels (ESLs) to kick traditional price tags to the curb. What started as a shake-up in supermarkets now rolls into the world of home improvement retail—headline by hagebaumarkt in Selb after nearly half...

Armenia's Mining Sector Eyes Future Opportunities

The Changing Landscape of Armenia's Mining Sector Crack open a map of Armenia, and you're staring at a mineral-rich ground ripe for opportunity. That's the lay of the land that the third annual Mining Armenia Forum 2026 zoomed in on, with more than 30 presentations tackling the future of responsible mining, investment, and technology. Taking over the mountain air in...

Stora Enso Plans Bold Demerger; Bergslagets Skogar to List

Stora Enso's Strategic Split: Bold Move or Risky Bet? There's something almost audacious about Stora Enso's decision to separate Bergslagets Skogar into its own publicly listed company. The board has given this demerger plan the green light, aiming to unravel a more refined operation out of Stora Enso's labyrinthine portfolio. It's a move that should have the suits on...

Summit Hotel Welcomes New CFO, Promotes Veteran COO

Summit Hotel Properties Shakes Up Leadership Ah, the hotel industry. Sometimes as glitz and glam as Beverly Hills, sometimes as harried as a concierge juggling suitcases. Now, Summit Hotel Properties is playing its hand, reshuffling the deck with some keen leadership moves. Swapping out the four of spades for some aces, if you ask me. On November 1st, they’re bringing...

P.S. Active Teams with Barrett for Logistics Boost

Barrett Gets in the Game with P.S. Active Alright, picture this: an activewear brand hooked up with a logistics heavyweight. No, it's not just another round of corporate muscle-flexing—it's P.S. Active, spearheaded by Erika Hammond, partnering with Barrett Distribution Centers to elevate their fulfillment game from New Jersey's Somerset hub. The Stakes: More Than Just...

Merchant of Tennis Data Breach Settlement Details Revealed

Settlement Reached in Data Breach Case Straight talk today about some pocketbook matters, folks. There's a class action settlement on the table for the Merchant of Tennis cyberattack crowd, and it's catching some eyes. The case stems from a 2024 hack on Merchant of Tennis, and a few other sibling companies, where sensitive files took a hike. Nobody’s fessing up to...

Midterms and Retirement: Evaluate Precious Metals

Understanding the Financial Climate Amid Midterms Here we go, folks—the red, white, and blue circus we know as the midterms is back in town. And while politicians do their song and dance, you gotta ask yourself if your investments are strong enough to weather any storm those election winds might blow your way. American Independence Gold is waving the flag, telling folks...

Broadway.com Instagram Reaches Million Followers Milestone

Broadway.com's Instagram Ascends to Iconic Status There it is, folks—Broadway.com's Instagram just threw down the gauntlet with a clean, million-follower milestone. That's right, a hefty chunk of people now have a front-row seat to Broadway's electric world, straight from their phones. If you're a Broadway buff or just a casual admirer of glitz and glam, these numbers...

Reducto Office Transforms Document Editing with AI

AI Meets Full-Fidelity Document Editing Gone are the days when AI could only analyze documents. With Reducto Office's latest plugin, the AI's stepping right into the editing game. For free, they say! Built smack-dab into ChatGPT and Codex, this plugin lets users work their AI magic on Word docs, PowerPoint presentations, and Excel spreadsheets. And the kicker? You can see...